How systemic sclerosis care has changed — what helps

Credibility

Interest

Share:2 min read

Key Takeaway

Over 25 years, treatments for systemic sclerosis (SSc) have shifted toward newer medicines that target blood vessels, the immune system, and lung scarring, especially at specialized centers.

What They Found

Doctors are using more drugs that help blood flow (like endothelin receptor blockers and prostacyclin-type drugs); use rose from about 3% in 2005 to 28% in 2025. Medicines that change the immune system (called immunomodulators) moved away from older drugs like cyclophosphamide and toward drugs such as mycophenolate, rituximab, and tocilizumab. A newer anti-scarring drug for the lungs, nintedanib, is being used more often and is often given together with other immune drugs. Use of steroids (glucocorticoids) has fallen a lot, from around half of patients in 2000 to under 20% in 2025, because doctors now favor other options. Where someone gets care matters: university and rheumatology centers use these newer immune and anti-scarring drugs more than non-university or dermatology clinics.

Who Should Care and Why

People with SSc and their caregivers should know that newer, targeted medicines are more available now and can help with blood flow problems and lung scarring—two common and serious SSc problems. If you have lung involvement (called interstitial lung disease, which is scarring in the lungs), the study found doctors are more likely to offer anti-scarring drugs like nintedanib; think of it like using a different tool when a house has water damage versus a wall scratch. Patients treated at university or rheumatology centers were more likely to get these newer options, so asking for a referral or a second opinion could matter, much like seeing a specialist for a tricky car repair. Caregivers can use this information to ask doctors about combination plans (for example, nintedanib plus mycophenolate) when lung scarring or skin thickening is present. Health care teams can use these results to match treatment to what matters most for each patient—breathing, skin changes, or heart involvement—rather than using one-size-fits-all therapy.

Important Considerations

This study looked at prescribing patterns in one large German group of clinics and may not reflect every country or doctor, so availability and choices could differ where you live. The study describes what doctors did, not a direct test proving one drug is better than another for every person, so talk with your doctor about what fits your health. Differences between clinics suggest some patients may need help getting care from teams that follow the latest guidelines.

AI-generated summary — for informational purposes only, not medical advice

Categories:

Treatment Updates Clinical Trials Living with MS

Article Topics:

DNSSFibrosisInflammationRegistrySScTreatmentVasculopathy

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Arthritis research & therapy often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News